Why most transporter mutations that cause antibiotic resistance are to efflux pumps rather than to import transporters

¹Pedro Mendes, ²Enrico Girardi, ^{2,3}Giulio Superti-Furga & Douglas B. Kell^{4,5*}

¹Center for Quantitative Medicine and Department of Cell Biology, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-6033, USA

² CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A-1090 Vienna, Austria

³ Center for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria.

⁴ Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Crown St, Liverpool L69 7ZB, UK

⁵ The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet 200, 2800 Kgs Lyngby, Denmark

***Correspondence:** Douglas B. Kell, dbk@liv.ac.uk ORCID 0000-0001-5838-7963.

27 Table of Contents

28	Why most transporter mutations that cause antibiotic resistance are to efflux pumps	
29	rather than to import transporters	1
30	Keywords.....	2
31	Abstract	3
32	Introduction.....	4
33	Materials and methods	6
34	Results	7
35	Discussion	9
36	Acknowledgements	10
37	Conflict of interest statement.....	10
38	Legends to figures	10
39	Supplementary information	10
40	Author contribution statement	10
41	References	10

42

43

44

45 Keywords

46

47

48 AMR – antimicrobial resistance – efflux pumps – transporters – antibiotics

Abstract

Genotypic microbial resistance to antibiotics with intracellular targets commonly arises from mutations that increase the activities of transporters (pumps) that cause the efflux of intracellular antibiotics. *A priori* it is not obvious why this is so much more common than are mutations that simply inhibit the activity of uptake transporters for the antibiotics. We analyse quantitatively a mathematical model consisting of one generic equilibrative transporter and one generic concentrative uptake transporter (representing any number of each), together with one generic efflux transporter. The initial conditions are designed to give an internal concentration of the antibiotic that is three times the minimum inhibitory concentration (MIC). The effect of varying the activity of each transporter type 100-fold is dramatically asymmetric, in that lowering the activities of individual uptake transporters has comparatively little effect on internal concentrations of the antibiotic. By contrast, increasing the activity of the efflux transporter lowers the internal antibiotic concentration to levels far below the MIC. Essentially, these phenomena occur because inhibiting individual influx transporters allows others to ‘take up the slack’, whereas increasing the activity of the generic efflux transporter cannot easily be compensated. The findings imply strongly that inhibiting efflux transporters is a much better approach for fighting antimicrobial resistance than is stimulating import transporters. This has obvious implications for the development of strategies to combat the development of microbial resistance to antibiotics and possibly also cancer therapeutics in human.

Introduction

In order to understand genotypic antimicrobial resistance and how to combat it, a starting point should be an understanding of the main kinds of mutation that can cause it. For present purposes, we assume that the molecular targets of the antibiotic are intracellular (and indeed when the microbes themselves are inside host cells, their access presents its own problems¹). Broadly, these mutations are of then of three kinds²⁻⁴: (i) mutations in or overproduction of one or more targets of the antibiotic (e.g. DNA gyrase and topoisomerase IV for ciprofloxacin⁵), (ii) mutations that lead to inactivation of the antibiotic (e.g. of chloramphenicol⁶ and aminoglycosides⁷), or (iii) mutations that affect the ability of the antibiotic to be transported to a compartment containing its sites of action in the target microbe.

To enter the target microbe, antibiotics (as do other drugs, e.g.⁸⁻¹⁴) require transporters. (In Gram-negatives, outer-membrane proteins may also play a role¹⁵⁻¹⁷.) The precise identities of these uptake transporters are in general not well understood, because mutations tend to lead only to partial resistance. However, they have been identified for antibiotics such as aminoglycosides¹⁸, chloramphenicol¹⁹, cycloserine²⁰ and fosfomycin^{21, 22}. In addition, bacteria have also evolved a variety of efflux pumps that serve to remove such antibiotics (see later, and also many other substances^{23, 24}) from the cells. Thus, mutations that affect transporter activity can in principle involve uptake transporters, efflux transporters, or upstream regulators of their activity. Our focus is on this collective class, viz. transporters. In particular, consistent with the difficulty of identifying transporters for their uptake, we note that the very great bulk of transporter-mediated resistance is mediated via (multi-drug) efflux rather than influx transporters (e.g.²⁵⁻⁴⁵). The focus of this article is to enquire as to the reasons why this might be so.

To this end, we create a very simple and generic model (Fig 1), consisting of two types of influx and one type of efflux transporter. For the influx transporters, one is a generic equilibrative transporter and one is concentrative for uptake, i.e. it has the capability of raising the concentration of the drug of interest to a higher level inside than outside. Such transporters necessarily require a source of free energy; in prokaryotes this is mainly ATP^{46, 47}. The effluxer is also taken to be ATP-

driven. We assume that a drug (antibiotic) has been added at 3x the minimum inhibitory concentration (MIC), which for our purposes is taken to be 1 concentration unit in the case of the wild type, but that the drug does not itself alter the expression levels of the transporters (cf. ⁴⁸).

Fig 1. The generic model in which we have a suite of (A) equilibrative and (B) concentrative influx transporters, together with a generic ATP-driven efflux transporter.

Intuitively, lowering the internal concentration of the drug by blocking the concentrative one only works if the equilibrative ones are collectively slower than an individual concentrator, and this is unlikely if there are several. Similarly, trying to lower the internal concentration by blocking one of the equilibrative ones would just let the concentrative one(s) 'pick up the slack'. This already suggests the general reason why a partial inhibition of uptake activity might have comparatively little effect. Of course if we start with the drug at a level above its MIC it is clear that increasing the effluxer activity can serve to bring to a level below the MIC (and that lowering any starting efflux activity would increase antibiotic sensitivity). We now wish to assess these intuitions by putting some concrete numbers on these fluxes. In systems biology ⁴⁹⁻⁵³, this is commonly done by casting the enzymatic rate equations into the form of ordinary differential equations, and this is what we do here.

Materials and methods

As previously⁵⁴, all simulations were performed using COPASI, here version 4.27, with the LSODA integrator⁵⁵⁻⁵⁷ (<http://copasi.org/>), which reads and writes SBML-compliant models⁵⁸⁻⁶⁰. It contains a full suite of enzyme rate equations, and admits automated parameter sweeps. Model files including the precise parameters are included as supplementary data.

The simulations were carried out with a differential equation-based model with three compartments (Fig 1), viz. the intracellular space, the inner membrane, and the extracellular space (including the periplasmic volume). Three different transporters are considered: transporter *A* is an equilibrator that allows transport in both directions ($K_{eq} = 1$), *B* is a concentrative influx transporter; even though allowing transport in both directions, it favors transport into the cell (modelled by setting $K_{eq} = 10$ or $K_{eq} = 100$). *C* is an efflux pump that only transports the drug from the cytoplasm to the outside.

The model was set up to mimic typical assays, and parameters were set to values that are comparable to what is found in the literature as follows. Total volume of the assay is 150 μl (from⁶¹). Each assay is estimated to have 10^6 cells, with an average volume of 4×10^{-15} l per cell⁶² (grown in rich media). Estimates of the proportion of volume taken by the periplasm are around 30%⁶³. Thus, the total cell volume in the assay is estimated at 4×10^{-9} l and the cytoplasmic volume at 2.8×10^{-9} l. For the inner membrane surface area we adopt the average value in the range considered by Wong and Amir⁶⁴ $34.5 \mu\text{m}^2$ ($3.45 \times 10^{-7} \text{ cm}^2$), which corresponds to a total surface area of 0.345 cm^2 (i.e. for all 10^6 cells); note that Thanassi *et al.* provide an estimate 3-fold lower (0.103 cm^2)⁶⁵.

Kinetic parameters for the efflux pump (*C*) come from Nagano and Nikaido for AcrB (part of *acrAB/tolC*) with nitrocefin⁶⁶; they cite a K_m of 5 μM , k_{cat} of 10 s^{-1} and a V_{max} of $2.35 \times 10^{-11} \text{ mol/s/10}^9$ cells, which implies a total of $2.35 \times 10^{-12} \text{ mol}$ of transporter. Considering that our simulation contains 10^6 cells, the adjusted amount of transporter is then $2.35 \times 10^{-15} \text{ mol}$

(considering the surface area estimated above, this corresponds to a surface density of 6.8×10^{-15} mol/cm²) with a V_{max} of 2.35×10^{-14} mol/s, assuming the same k_{cat} as for nitrocefin. For K_m we chose a higher value (500 μ M).

Results

Fig 2 shows our 'baseline simulation, in which a steady-state intracellular level of the drug similar to that outside is obtained by balancing the three main fluxes.

Fig 2 Effect of varying the relative rates of the three generic transporters individually on the normalized accumulation of an antibiotic. Parameters as in Methods and the supplementary files, with K_{eq} for transporter B set at 10.

It is clear that there is a very strong asymmetry; decreasing the individual activities of the equilibrative or concentrative transporters even 100-fold has only a 1.63- or 2.33-fold effect on the steady-state intracellular concentration of the drug, while increasing the effluxer activity by the same amount lowers the intracellular concentration fifty-fold.

Changing the (maximal) degree to which the concentrator concentrates (viz 100-fold rather than 10-fold) also has no material effect on the results when individual transporter activities are lowered, and only a marginal effect when the activity of the concentrator is raised (Fig 3, top right).

Fig 3. Effect of varying the relative rates of the three generic transporters on the normalized accumulation of an antibiotic. Parameters as in Methods and the supplementary files, with K_{eq} for transporter B set at 100.

Discussion

Microbial resistance to antibiotics (AMR) remains a huge problem (e.g. ⁶⁷⁻⁷²). To this end, a major cause is the ability of efflux pumps to create resistance to antibiotics by pumping them out from the cytoplasm of cells (e.g. ²⁵⁻⁴⁵). This is true for cytotoxic substances more generally, including anti-cancer drugs ^{42, 48}. Many efflux transporters are sufficiently active that even when the drug has relatively tight intracellular binding sites they can effectively remove almost all of it, as is the case with AcrAB/TolC and ethidium bromide ^{73, 74}. A recent experimental survey of several hundred gene knockouts in *E. coli*, using fluorescent probes as antibiotic surrogates showed that dozens of such efflux transporters could be active and thereby contribute to lowering the steady-state uptake ⁴⁷. There is also considerable redundancy and plasticity ⁷⁵. Thus, as expected from metabolic control analysis, while there is little effect of single-gene knockouts on fluxes ⁷⁶, there can be potentially very large effects on the concentrations of intermediary metabolites ^{77, 78} or, as in our model, the intracellular concentration of an antibiotic of interest,

If there is only a single influx transporter (or one that is overwhelmingly dominant) for a cytotoxic drug of interest, as occasionally happens ¹³, inhibiting it can lower the toxicity of the drug enormously; in the case of YM155 (sepantronium bromide) this could be by several hundredfold ¹³. However, it is possible that mutation of a non-redundant influx transporter might also induce significant metabolic costs, although there are also constraints ⁷⁹. Moreover, most cytotoxic drugs can be taken up by multiple transporters ^{80, 81}, and affecting all of them simultaneously is probably not realistic.

The consequences of our simple model are thus clear: in order to inhibit the development of antimicrobial resistance, we need to be able to inhibit the efflux pumps that such bacteria possess and use in abundance. To this end, it is indeed widely considered that inhibitors of efflux pumps might well have a role to play in reducing AMR ^{42, 82-85}. The present simulations put this thinking on a firm and quantitative footing.

202

203

204

205 **Acknowledgements**

206 DBK thanks the BBSRC (grants BB/P009042/1 and BB/R000093/1), the Novo Nordisk Fonden via
 207 the Centre for Biosustainability (grant NNF10CC1016517), and the University of Liverpool for
 208 financial support. PM thanks the NIH (grants GM115043 and GM127909) for financial support. EG
 209 and GSF acknowledge supports from the Austrian Academy of Sciences and the European
 210 Research Council (ERC AdG 695214 GameofGates).

211

212 **Conflict of interest statement**

213 The authors declare that they have no conflicts of interest.

214

215 **Legends to figures**

216 (above)

217 **Supplementary information**

218 A zip file containing the COPASI model and results files.

219

220 **Author contribution statement**

221 EG and GSF originally posed the problem to DBK. DBK defined a suitable system and suggested
 222 the idea of modelling it. PM ran all the simulations. All authors contributed to the writing of the ms.

223

224 **References**

225

- 226 1. Prideaux, B. et al. The association between sterilizing activity and drug distribution into
 227 tuberculosis lesions. *Nat Med* **21**, 1223-1227 (2015).
- 228 2. McKeegan, K.S., Borges-Walmsley, M.I. & Walmsley, A.R. Microbial and viral drug
 229 resistance mechanisms. *Trends Microbiol* **10**, S8-14 (2002).
- 230 3. Strateva, T. & Yordanov, D. *Pseudomonas aeruginosa* - a phenomenon of bacterial
 231 resistance. *J Med Microbiol* **58**, 1133-1148 (2009).
- 232 4. Munita, J.M. & Arias, C.A. Mechanisms of Antibiotic Resistance. *Microbiol Spectrum* **4**,
 233 VMBF-0016-2015 (2016).
- 234 5. Rehman, A., Patrick, W.M. & Lamont, I.L. Mechanisms of ciprofloxacin resistance in
 235 *Pseudomonas aeruginosa*: new approaches to an old problem. *J Med Microbiol* **68**, 1-10
 236 (2019).
- 237 6. Shaw, W.V. et al. Primary structure of a chloramphenicol acetyltransferase specified by R
 238 plasmids. *Nature* **282**, 870-872 (1979).

- 239 7. Ramirez, M.S. & Tolmasky, M.E. Aminoglycoside modifying enzymes. *Drug Resist Updat*
240 **13**, 151-171 (2010).
- 241 8. Dobson, P.D. & Kell, D.B. Carrier-mediated cellular uptake of pharmaceutical drugs: an
242 exception or the rule? *Nat Rev Drug Disc* **7**, 205-220 (2008).
- 243 9. Fromm, M.F. & Kim, R.B. (eds.) Drug Transporters, Vol. 201. (Springer, Berlin; 2011).
- 244 10. You, G. & Morris, M.E. (eds.) Drug Transporters: Molecular Characterization and Role in
245 Drug Disposition, Edn. 2nd. (Wiley, New York; 2014).
- 246 11. Kell, D.B., Dobson, P.D., Bilsland, E. & Oliver, S.G. The promiscuous binding of
247 pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to)
248 know and how we can do so. *Drug Disc Today* **18**, 218-239 (2013).
- 249 12. Kell, D.B. & Oliver, S.G. How drugs get into cells: tested and testable predictions to help
250 discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. *Front*
251 *Pharmacol* **5**, 231 (2014).
- 252 13. Winter, G.E. et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage
253 toxicity. *Nat Chem Biol* **10**, 768-773 (2014).
- 254 14. Giacomini, K.M., Galetin, A. & Huang, S.M. The International Transporter Consortium:
255 Summarizing Advances in the Role of Transporters in Drug Development. *Clin Pharmacol*
256 *Ther* **104**, 766-771 (2018).
- 257 15. Hancock, R.E.W. The bacterial outer membrane as a drug barrier. *Trends Microbiol* **5**, 37-
258 42 (1997).
- 259 16. Bajaj, H. et al. Antibiotic uptake through membrane channels: role of *Providencia stuartii*
260 OmpPst1 porin in carbapenem resistance. *Biochemistry* **51**, 10244-10249 (2012).
- 261 17. Mahendran, K.R., Kreir, M., Weingart, H., Fertig, N. & Winterhalter, M. Permeation of
262 antibiotics through *Escherichia coli* OmpF and OmpC porins: screening for influx on a
263 single-molecule level. *J Biomol Screen* **15**, 302-307 (2010).
- 264 18. Taber, H.W., Mueller, J.P., Miller, P.F. & Arrow, A.S. Bacterial uptake of aminoglycoside
265 antibiotics. *Microbiol Rev* **51**, 439-457 (1987).
- 266 19. Prabhala, B.K. et al. The prototypical proton-coupled oligopeptide transporter YdgR from
267 *Escherichia coli* facilitates chloramphenicol uptake into bacterial cells. *J Biol Chem* **293**,
268 1007-1017 (2018).
- 269 20. Chen, J.M., Uplekar, S., Gordon, S.V. & Cole, S.T. A point mutation in *cycA* partially
270 contributes to the D-cycloserine resistance trait of *Mycobacterium bovis* BCG vaccine
271 strains. *PLoS One* **7**, e43467 (2012).
- 272 21. Takahata, S. et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of
273 *Escherichia coli*. *Int J Antimicrob Agents* **35**, 333-337 (2010).
- 274 22. Ballesterio-Téllez, M. et al. Molecular insights into fosfomycin resistance in *Escherichia coli*.
275 *J Antimicrob Chemother* **72**, 1303-1309 (2017).
- 276 23. Kell, D.B., Swainston, N., Pir, P. & Oliver, S.G. Membrane transporter engineering in
277 industrial biotechnology and whole-cell biocatalysis. *Trends Biotechnol* **33**, 237-246 (2015).
- 278 24. Kell, D.B. in Fermentation microbiology and biotechnology, 4th Ed. (eds. E.M.T. El-Mansi,
279 J. Nielsen, D. Mousdale, T. Allman & R. Carlson) 117-138 (CRC Press, Boca Raton; 2019).
- 280 25. Phillips-Jones, M.K. & Harding, S.E. Antimicrobial resistance (AMR) nanomachines-
281 mechanisms for fluoroquinolone and glycopeptide recognition, efflux and/or deactivation.
282 *Biophys Rev* **10**, 347-362 (2018).
- 283 26. Chopra, I. & Roberts, M. Tetracycline antibiotics: Mode of action, applications, molecular
284 biology, and epidemiology of bacterial resistance. *Microbiol Mol Biol Rev* **65**, 232-+ (2001).
- 285 27. Alekshun, M.N. & Levy, S.B. Molecular mechanisms of antibacterial multidrug resistance.
286 *Cell* **128**, 1037-1050 (2007).
- 287 28. Bhardwaj, A.K. & Mohanty, P. Bacterial efflux pumps involved in multidrug resistance and
288 their inhibitors: rejuvenating the antimicrobial chemotherapy. *Recent Pat Antiinfect Drug*
289 *Discov* **7**, 73-89 (2012).
- 290 29. Nikaido, H. & Pagès, J.M. Broad-specificity efflux pumps and their role in multidrug
291 resistance of Gram-negative bacteria. *FEMS Microbiol Rev* **36**, 340-363 (2012).
- 292 30. Blair, J.M., Richmond, G.E. & Piddock, L.J.V. Multidrug efflux pumps in Gram-negative
293 bacteria and their role in antibiotic resistance. *Future Microbiol* **9**, 1165-1177 (2014).
- 294 31. Delmar, J.A., Su, C.C. & Yu, E.W. Bacterial multidrug efflux transporters. *Annu Rev*
295 *Biophys* **43**, 93-117 (2014).

32. Sun, J., Deng, Z. & Yan, A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. *Biochem Biophys Res Commun* **453**, 254-267 (2014).
33. Anes, J., McCusker, M.P., Fanning, S. & Martins, M. The ins and outs of RND efflux pumps in *Escherichia coli*. *Front Microbiol* **6**, 587 (2015).
34. Li, X.Z., Plésiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin Microbiol Rev* **28**, 337-418 (2015).
35. Hernando-Amado, S. et al. Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials. *Drug Resist Updat* **28**, 13-27 (2016).
36. Alibert, S. et al. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective. *Expert Opin Drug Met Toxicol* **13**, 301-309 (2017).
37. Hassan, K.A. et al. The putative drug efflux systems of the *Bacillus cereus* group. *PLoS One* **12**, e0176188 (2017).
38. Yilmaz, Ç. & Özcengiz, G. Antibiotics: Pharmacokinetics, toxicity, resistance and multidrug efflux pumps. *Biochem Pharmacol* **133**, 43-62 (2017).
39. Ahmad, I. et al. Bacterial Multidrug Efflux Proteins: A Major Mechanism of Antimicrobial Resistance. *Curr Drug Targets* **19** (2018).
40. Du, D. et al. Multidrug efflux pumps: structure, function and regulation. *Nat Rev Microbiol* **16**, 523-539 (2018).
41. Zgurskaya, H.I., Rybenkov, V.V., Krishnamoorthy, G. & Leus, I.V. Trans-envelope multidrug efflux pumps of Gram-negative bacteria and their synergism with the outer membrane barrier. *Res Microbiol* (2018).
42. Alexa-Stratulat, T., Pešić, M., Gašparović, A.Č., Trougakos, I.P. & Riganti, C. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. *Drug Resist Updat* **46**, 100643 (2019).
43. Piddock, L.J.V. The 2019 Garrod Lecture: MDR efflux in Gram-negative bacteria-how understanding resistance led to a new tool for drug discovery. *J Antimicrob Chemother* **74**, 3128-3134 (2019).
44. Ricci, V., Tzakas, P., Buckley, A. & Piddock, L.J. Ciprofloxacin-resistant *Salmonella enterica* serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. *Antimicrob Agents Chemother* **50**, 38-42 (2006).
45. Blair, J.M.A., Webber, M.A., Baylay, A.J., Ogbolu, D.O. & Piddock, L.J.V. Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol* **13**, 42-51 (2015).
46. Darbani, B., Kell, D.B. & Borodina, I. Energetic evolution of cellular transportomes *BMC Genomics* **19**, 418 (2018).
47. Jindal, S., Yang, L., Day, P.J. & Kell, D.B. Involvement of multiple influx and efflux transporters in the accumulation of cationic fluorescent dyes by *Escherichia coli*. *BMC Microbiol* **19**, 195; also bioRxiv 603688v603681 (2019).
48. Grixti, J., O'Hagan, S., Day, P.J. & Kell, D.B. Enhancing drug efficacy and therapeutic index through cheminformatics-based selection of small molecule binary weapons that improve transporter-mediated targeting: a cytotoxicity system based on gemcitabine. *Front Pharmacol* **8**, 155 (2017).
49. Klipp, E., Herwig, R., Kowald, A., Wierling, C. & Lehrach, H. Systems biology in practice: concepts, implementation and clinical application. (Wiley/VCH, Berlin; 2005).
50. Alon, U. An introduction to systems biology: design principles of biological circuits. (Chapman and Hall/CRC, London; 2006).
51. Kell, D.B. & Knowles, J.D. in System modeling in cellular biology: from concepts to nuts and bolts. (eds. Z. Szallasi, J. Stelling & V. Periwal) 3-18 (MIT Press, Cambridge; 2006).
52. Kell, D.B. Metabolomics, modelling and machine learning in systems biology: towards an understanding of the languages of cells. The 2005 Theodor Bücher lecture. *FEBS J* **273**, 873-894 (2006).
53. Palsson, B.Ø. Systems biology: simulation of dynamics network states. (Cambridge University Press, Cambridge; 2011).
54. Mendes, P., Oliver, S.G. & Kell, D.B. Fitting transporter activities to cellular drug concentrations and fluxes: why the bumblebee can fly. *Trends Pharmacol Sci* **36**, 710-723 (2015).
55. Bergmann, F.T. et al. COPASI and its applications in biotechnology. *J Biotechnol* **261**, 215-220 (2017).

56. Hoops, S. et al. COPASI: a COMplex PATHway Simulator. *Bioinformatics* **22**, 3067-3074 (2006).
57. Mendes, P. et al. Computational modeling of biochemical networks using COPASI. *Methods Mol Biol* **500**, 17-59 (2009).
58. Hucka, M. et al. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. *Bioinformatics* **19**, 524-531 (2003).
59. Hucka, M. et al. The Systems Biology Markup Language (SBML): Language Specification for Level 3 Version 1 Core. *J Integr Bioinform* **12**, 266 (2015).
60. Hucka, M. et al. The Systems Biology Markup Language (SBML): Language Specification for Level 3 Version 2 Core Release 2. *J Integr Bioinform* **16** (2019).
61. Iyer, R., Ferrari, A., Rijnbrand, R. & Erwin, A.L. A fluorescent microplate assay quantifies bacterial efflux and demonstrates two distinct compound binding sites in AcrB. *Antimicrob Agents Chemother* **59**, 2388-2397 (2015).
62. Volkmer, B. & Heinemann, M. Condition-dependent cell volume and concentration of *Escherichia coli* to facilitate data conversion for systems biology modeling. *PLoS One* **6**, e23126 (2011).
63. Stock, J.B., Rauch, B. & Roseman, S. Periplasmic space in *Salmonella typhimurium* and *Escherichia coli*. *J Biol Chem* **252**, 7850-7861 (1977).
64. Wong, F. & Amir, A. Mechanics and Dynamics of Bacterial Cell Lysis. *Biophys J* **116**, 2378-2389 (2019).
65. Thanassi, D.G., Suh, G.S. & Nikaido, H. Role of outer membrane barrier in efflux-mediated tetracycline resistance of *Escherichia coli*. *J Bacteriol* **177**, 998-1007 (1995).
66. Nagano, K. & Nikaido, H. Kinetic behavior of the major multidrug efflux pump AcrB of *Escherichia coli*. *Proc Natl Acad Sci* **106**, 5854-5858 (2009).
67. Roca, I. et al. The global threat of antimicrobial resistance: science for intervention. *New Microbes New Infect* **6**, 22-29 (2015).
68. Laxminarayan, R., Sridhar, D., Blaser, M., Wang, M. & Woolhouse, M. Achieving global targets for antimicrobial resistance. *Science* **353**, 874-875 (2016).
69. Gelband, H. & Laxminarayan, R. Tackling antimicrobial resistance at global and local scales. *Trends Microbiol* **23**, 524-526 (2015).
70. Andersson, D.I. & Hughes, D. Antibiotic resistance and its cost: is it possible to reverse resistance? *Nat Rev Microbiol* **8**, 260-271 (2010).
71. Baker, S., Thomson, N., Weill, F.X. & Holt, K.E. Genomic insights into the emergence and spread of antimicrobial-resistant bacterial pathogens. *Science* **360**, 733-738 (2018).
72. Jindal, S., Thampy, H., Day, P.J. & Kell, D.B. Very rapid flow cytometric assessment of antimicrobial susceptibility during the apparent lag phase of bacterial (re)growth *Microbiology* **165**, 439-454 (2019).
73. Jernaes, M.W. & Steen, H.B. Staining of *Escherichia coli* for flow cytometry: influx and efflux of ethidium bromide. *Cytometry* **17**, 302-309 (1994).
74. Walberg, M., Gaustad, P. & Steen, H.B. Rapid preparation procedure for staining of exponentially growing *P. vulgaris* cells with ethidium bromide: a flow cytometry-based study of probe uptake under various conditions. *J. Microbiol. Methods* **34**, 49-58 (1998).
75. Cudkowicz, N.A. & Schuldiner, S. Deletion of the major *Escherichia coli* multidrug transporter AcrB reveals transporter plasticity and redundancy in bacterial cells. *Plos One* **14** (2019).
76. Ishii, N. et al. Multiple high-throughput analyses monitor the response of *E. coli* to perturbations. *Science* **316**, 593-597 (2007).
77. Kell, D.B. & Westerhoff, H.V. Metabolic control theory: its role in microbiology and biotechnology. *FEMS Microbiol. Rev.* **39**, 305-320 (1986).
78. Fell, D.A. Understanding the control of metabolism. (Portland Press, London; 1996).
79. Zampieri, M. et al. Metabolic constraints on the evolution of antibiotic resistance. *Mol Syst Biol* **13**, 917 (2017).
80. Lanthaler, K. et al. Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast. *BMC Biol* **9**, 70 (2011).
81. Girardi, E. et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. *bioRxiv*, 726539v726531 (2019).

- 410 82. Annunziato, G. Strategies to Overcome Antimicrobial Resistance (AMR) Making Use of
411 Non-Essential Target Inhibitors: A Review. *Int J Mol Sci* **20** (2019).
- 412 83. Lamut, A., Peterlin Mašič, L., Kikelj, D. & Tomašič, T. Efflux pump inhibitors of clinically
413 relevant multidrug resistant bacteria. *Med Res Rev* **39**, 2460-2504 (2019).
- 414 84. Grimsey, E.M. & Piddock, L.J.V. Do phenothiazines possess antimicrobial and efflux
415 inhibitory properties? *FEMS Microbiol Rev* (2019).
- 416 85. Lomovskaya, O. et al. Identification and characterization of inhibitors of multidrug
417 resistance efflux pumps in *Pseudomonas aeruginosa*: novel agents for combination
418 therapy. *Antimicrob Agents Chemother* **45**, 105-116 (2001).
- 419